Novo Nordisk plots phase 3 trials for next-gen obesity asset amycretin
Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early next year.
The Danish pharma and obesity heavyweight is moving forward with both subcutaneous and oral versions of amycretin, a GLP-1 and amylin receptor agonist.
It was previously unclear what Novo was planning for the dual-acting candidate. Now, the pharma has shared that the decision to move forward is based on feedback from regulatory authorities after end-of-phase 2 interactions for both forms of amycretin, according to a June 12 release.
A phase 3 program enrolling adults with overweight or obesity is slated to start in the first quarter of 2026.
